22 June 2018

ASX Announcement

Release of Securities from Escrow

Race Oncology Limited (ASX: RAC, Race Oncology or the **Company**) hereby advises in accordance with ASX Listing Rule 3.10A that the following securities will be released from escrow:

Security	Number	Release Date
Ordinary Shares	27,341,434	13 July 2018
Performance Shares	10,000,000	13 July 2018
Options expiring 01/07/2018	10,000,000	13 July 2018
Options expiring 01/07/2021	9,000,000	13 July 2018

Peter Webse
Company Secretary

About Bisantrene
Bisantrene is a small-molecule chemotherapy drug related to the anthracyclines, the most frequently prescribed cancer drugs and first line of treatment for many cancers, but has been shown to have greatly reduced cardiac toxicity. Bisantrene was tested in more than 40 clinical studies before it was lost in a series of pharmaceutical mergers in the 1990s. The initial clinical opportunity for Bisantrene is for relapsed/refractory AML patients. Race owns two patents on the drug, both of which have received notice of allowance in the US, and has been granted an Orphan Drug Designation in the US for AML, which confers seven years of market exclusivity in US from date of FDA approval.

About Race Oncology (RAC.ASX)
Race Oncology is a specialty pharmaceutical company that listed on the Australian Securities Exchange (ASX) in July 2016. Race's business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug that was the subject of more than 40 phase II clinical studies during the 1980s and 1990s before it was lost in a series of big pharma mergers.

Media contact:

Heidi Cuthbert
0411 272 366
E: heidi.cuthbert@multiplier.com.au